A panel of U.S. vaccine experts met Wednesday to discuss key questions for future COVID-19 booster campaigns. The FDA's vaccine advisers won’t make any binding decisions, but they could help shape the government’s approach for years to come.
PUBLISHED 10:12 AM EDT Apr. 07, 2022While many Americans are trying to move on with their lives after two years of the COVID-19 pandemic, U.S. health officials are debating the best way to use vaccines to stay ahead of the coronavirus.Members of the FDA's Vaccines and Related Biological Products Advisory Committee met Wednesday to discuss key questions for future COVID-19 booster campaigns
A panel of U.S. vaccine experts met Wednesday to discuss key questions for future COVID-19 booster campaigns. The Food and Drug Administration’s vaccine advisers won’t make any binding decisions, but they could help shape the government’s approach for years to come. “What really keeps me up at night is the knowledge that we can’t keep boosting and that we only — we’re gonna have vaccine exhaustion," Marks said. "And I’m not talking about immune exhaustion, I’m talking about physical exhaustion of people not going to get boosted."
Only about half of Americans eligible for a third shot have gotten one. And some independent experts disagree about the need for even that additional protection in healthy individuals, due to limited evidence of the benefit or how long it might last. COVID-19 cases have dropped to low levels in the U.S., but health officials are warily watching an omicron sibling that now accounts for most cases.
The timeline for updating annual flu vaccines offers one possible model, and the FDA panel discussed the strengths and weakness of adopting such an approach.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Covid jabs: Why families are taking their children for a Covid vaccineChildren having the vaccination in Derby say the experience made their worries go.
続きを読む »
Covid-19: Two Covid-related deaths and 519 in hospitalThe total number of deaths linked to Covid-19 in NI since the start of the pandemic is 3,348.
続きを読む »
Current COVID vaccines not 'well-matched' against BA.2 -FDAThe FDA, however, said booster shots protect against serious outcomes of COVID-19, compared with the two preliminary doses. U.S. health officials in late March authorized a second booster dose of Moderna and Pfizer's vaccines for people aged 50 and older, citing data showing waning immunity and risks posed by Omicron variants of the virus. 'This discussion today is a much larger discussion - it's a discussion for what do we do about the entire population, and what do we do when we think the virus has evolved further,' said Peter Marks, director of the FDA's Center for Biologics Evaluation and Research.
続きを読む »
FDA Committee Agrees Continued COVID-19 Boosting Not SustainableThe agency’s expert panel met to outline a more systematic way of approaching COVID-19 vaccination and boosting
続きを読む »
The FDA is inching closer to a long-term COVID booster planAfter authorizing a second booster for elderly Americans, the FDA is consulting with advisors on a COVID booster strategy that address future variants and vaccine development.
続きを読む »